miltefosine has been researched along with Diarrhea in 3 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "There is still no effective treatment for cryptosporidiosis even though the disease has a significant impact on HIV-infected adults and children." | 6.76 | In a trial of the use of miltefosine to treat HIV-related cryptosporidiosis in Zambian adults, extreme metabolic disturbances contribute to high mortality. ( Katubulushi, M; Kelly, P; Obwaller, A; Sianongo, S; Sinkala, E, 2011) |
| "There is still no effective treatment for cryptosporidiosis even though the disease has a significant impact on HIV-infected adults and children." | 2.76 | In a trial of the use of miltefosine to treat HIV-related cryptosporidiosis in Zambian adults, extreme metabolic disturbances contribute to high mortality. ( Katubulushi, M; Kelly, P; Obwaller, A; Sianongo, S; Sinkala, E, 2011) |
| "Miltefosine is an oral drug which was used as a topical application for skin metastasis of breast cancer." | 1.43 | Pharmacovigilance of Miltefosine in Treatment of Visceral Leishmaniasis in Endemic Areas of Bihar, India. ( Das Gupta, RK; Das, P; Dhariwal, AC; Pandey, K; Ravidas, V; Siddiqui, NA; Singh, TP; Sinha, SK; Verma, RB, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pandey, K | 1 |
| Ravidas, V | 1 |
| Siddiqui, NA | 1 |
| Sinha, SK | 1 |
| Verma, RB | 1 |
| Singh, TP | 1 |
| Dhariwal, AC | 1 |
| Das Gupta, RK | 1 |
| Das, P | 1 |
| Sinkala, E | 1 |
| Katubulushi, M | 1 |
| Sianongo, S | 1 |
| Obwaller, A | 1 |
| Kelly, P | 1 |
| Sundar, S | 1 |
| Makharia, A | 1 |
| More, DK | 1 |
| Agrawal, G | 1 |
| Voss, A | 1 |
| Fischer, C | 1 |
| Bachmann, P | 1 |
| Murray, HW | 1 |
2 trials available for miltefosine and Diarrhea
| Article | Year |
|---|---|
In a trial of the use of miltefosine to treat HIV-related cryptosporidiosis in Zambian adults, extreme metabolic disturbances contribute to high mortality.
Topics: Adult; AIDS-Related Opportunistic Infections; Cryptosporidiosis; Diarrhea; Early Termination of Clin | 2011 |
Short-course of oral miltefosine for treatment of visceral leishmaniasis.
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Diarrhea; Drug Administration Schedule; Female; H | 2000 |
1 other study available for miltefosine and Diarrhea
| Article | Year |
|---|---|
Pharmacovigilance of Miltefosine in Treatment of Visceral Leishmaniasis in Endemic Areas of Bihar, India.
Topics: Administration, Oral; Adolescent; Adult; Aged; Alanine Transaminase; Antiprotozoal Agents; Aspartate | 2016 |